CMPS

Compass Pathways

4.57 USD
+0.15
3.39%
At close Feb 14, 4:00 PM EST
After hours
4.64
+0.07
1.53%
1 day
3.39%
5 days
1.56%
1 month
36.01%
3 months
-6.54%
6 months
-33.48%
Year to date
10.12%
1 year
-56.14%
5 years
-84.24%
10 years
-84.24%
 

About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Employees: 186

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

16% more capital invested

Capital invested by funds: $179M [Q2] → $208M (+$28.9M) [Q3]

7% more funds holding

Funds holding: 121 [Q2] → 129 (+8) [Q3]

4.52% more ownership

Funds ownership: 43.4% [Q2] → 47.92% (+4.52%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 28

46% less call options, than puts

Call options by funds: $4.21M | Put options by funds: $7.82M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
294%
upside
Avg. target
$29
535%
upside
High target
$40
775%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
40% 1-year accuracy
70 / 173 met price target
775%upside
$40
Buy
Maintained
13 Feb 2025
RBC Capital
Leonid Timashev
36% 1-year accuracy
16 / 44 met price target
294%upside
$18
Outperform
Reiterated
15 Jan 2025

Financial journalist opinion

Neutral
Business Wire
1 week ago
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference at 8:40 am ET on February 12th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be.
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Neutral
Business Wire
3 weeks ago
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by.
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer
Neutral
Business Wire
1 month ago
Compass Pathways Announces Pricing of Underwritten Offering
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one.
Compass Pathways Announces Pricing of Underwritten Offering
Neutral
Business Wire
1 month ago
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either bi.
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
Neutral
Business Wire
2 months ago
Compass Pathways to Participate in December Investor Conferences
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings: 7th Annual Evercore ISI HealthCONx Conference: Fireside chat at 10:25am ET on December 3, 2024 Piper Sandler 36th Annual Healthcare Conference: Fireside ch.
Compass Pathways to Participate in December Investor Conferences
Neutral
GlobeNewsWire
3 months ago
Compass Pathways to participate in Stifel 2024 Healthcare Conference
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.
Compass Pathways to participate in Stifel 2024 Healthcare Conference
Positive
Proactive Investors
3 months ago
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noting that psychedelics have reportedly helped his family and friends recover from trauma, severe depression and obsessive-compulsive disorder.
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
Positive
Benzinga
3 months ago
Top 3 Health Care Stocks You'll Regret Missing In November
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks You'll Regret Missing In November
Positive
Seeking Alpha
3 months ago
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Compass Pathways plc obtained positive results from phase 2b study using COMP360 for treatment resistant depression patients; Primary endpoint met with statistically significant p-value of p
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Neutral
The Motley Fool
3 months ago
Compass Pathways' Losses Widen in Q3
With its clinical trials at a pivotal stage, Compass Pathways is burning more cash, but reported a slightly narrower-than-expected net loss.
Compass Pathways' Losses Widen in Q3
Charts implemented using Lightweight Charts™